(76 days)
No
The document explicitly states "Mentions AI, DNN, or ML: Not Found" and the device description focuses on mechanical ultrafiltration and software for controlling the process, with no mention of AI/ML capabilities.
Yes
The device is indicated for "ultrafiltration treatment of patients with fluid overload," which is directly addressing a medical condition to restore health.
No
Explanation: The device is described as an "ultrafiltration treatment" system that removes excess fluid from patients. It is a therapeutic device, not a diagnostic one. Its purpose is to treat a condition (fluid overload), not to identify or characterize it.
No
The device description explicitly states the system is comprised of a console mounted on a cart, proprietary software, and accessories (catheters, extensions, and a blood pump circuit), indicating it includes significant hardware components beyond just software.
Based on the provided information, the Aquadex FlexFlow System is not an IVD (In Vitro Diagnostic).
Here's why:
- IVDs are used to examine specimens derived from the human body. The Aquadex FlexFlow System directly treats the patient by filtering their blood.
- The intended use describes a treatment for fluid overload. This is a therapeutic intervention, not a diagnostic test.
- The device description details a system for ultrafiltration of blood. This is an extracorporeal therapy, not a method for analyzing biological samples.
The Aquadex FlexFlow System is a medical device used for therapeutic purposes, specifically ultrafiltration.
N/A
Intended Use / Indications for Use
The Aquadex FlexFlow™ System is indicated for:
- Temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload . who have failed diuretic therapy, and
- Extended (longer than 8 hours) ultrafiltration treatment of patients with fluid . overload who have failed diuretic therapy and require hospitalization.
All treatments must be administered by a health care provider, under physician prescription, both of whom having received training in extracorporeal therapies.
Product codes
KDI
Device Description
The Aquadex FlexFlow System removes excess fluid from the patient in fluid overload by ultrafiltration of blood across a hollow-fiber hemofilter at the clinician selected rate. The system is comprised on a console mounted on a cart, proprietary software and accessories (venous access catheters, extensions and a blood pump circuit). Patient access is obtained via either peripheral or central venous veins.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
health care provider, under physician prescription
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Regression testing was performed to verify and validate the software change and to generate data in support of the labeling change which incorporates a catheter compatibility chart using the principles of ISO 14971:2000 "Medical devices - Application of risk management to medical devices. Data generated demonstrated the Aquadex FlexFlow System continues to be safe and effective.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5860 High permeability hemodialysis system.
(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”
0
OF 1 PAGE
| K062922 | |
|---|---|
| -- | --------- |
510(k) Summary (Prepared on September 26th, 2006)
10(k) Summary is submitted in accordance with 21 CFR 807.92.
| DEC 1 3 2006 | |
|---|---|
| -- | -------------- |
Aquadex FlexFlow™ System (trademark pending)
CHF Solutions, Inc., Suite 170 - 7601 Northland Drive, Brooklyn Park, MN 55428
| Chris Scavotto | Telephone: 763-463-4621 |
|---|---|
| QA Director | Fax: 763-463-4606 |
Ultrafiltration (Aquapheresis) System
High permeability dialysis systems - classified as Class II
Aquadex FlexFlow System (K060008)
| Predicate
Devices: | Aquadex FlexFlow System
(K060008) |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device
Description: | The Aquadex FlexFlow System removes excess fluid from the patient in fluid
overload by ultrafiltration of blood across a hollow-fiber hemofilter at the
clinician selected rate. The system is comprised on a console mounted on a
cart, proprietary software and accessories (venous access catheters,
extensions and a blood pump circuit). Patient access is obtained via either
peripheral or central venous veins. |
| Indication
for Use: | The Aquadex FlexFlowTM System is indicated for:
• Temporary (up to 8 hours) ultrafiltration treatment of patients with fluid
overload who have failed diuretic therapy, and
• Extended (longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require hospitalization.
All treatments must be administered by a health care provider, under
physician prescription, both of whom having received training in
extracorporeal therapies. |
| Safety &
Performance: | Regression testing was performed to verify and validate the software change
and to generate data in support of the labeling change which incorporates a
catheter compatibility chart using the principles of ISO 14971:2000 "Medical
devices - Application of risk management to medical devices. Data
generated demonstrated the Aquadex FlexFlow System continues to be safe
and effective. |
| Conclusion: | Based on the similar intended use, patient population, technology
characteristics, and performance as assessed |
This 510(
Trade Names:
Manufacturer:
Generic Name:
Classification:
Official Contact:
Device
CHF Solutions, Inc. Aquadex FlexFlow Rev. K Software Update
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with three swooping lines representing its wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850
Mr. Chris Scavotto Director of Quality Assurance CHF Solutions, Inc. 7601 Northland Dr., Ste. 170 BROOKLYN PARK MN 55428
DEC 1 3 2006
Re: K062922
Trade/Device Name: Aquadex™ FlexFlow™ System Regulation Number: 21 CFR §876.5860 Regulation Name: High permeability hemodialysis system Regulatory Class: II Product Code: KDI Dated: October 30, 2006 Received: November 13, 2006
Dear Mr. Scavotto:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Image /page/1/Picture/10 description: The image is a black and white circular logo. The logo has the letters "FDA" in a stylized font in the center. Above the letters, the numbers "1906-2006" are printed. Below the letters, the word "Centennial" is printed. The logo is surrounded by a circular border with text.
oling and Promoting Public Health
2
Page 2 -
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology) | 240-276-0115 |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-0115 |
| 21 CFR 894.xxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150
or at its Internet address http://www.fda.gov/cdrlv/industry/support/index.html.
Sincerely yours,
Nancy Cbrogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
INDICATIONS FOR USE STATEMENT (Page 1 of 1)
510(k) Number (if known): K06 2G 22
Device Name: Aquadex FlexFlow™ System
FDA's Statement of the Indication For Use for Device:
The Aquadex FlexFlow™ System is indicated for:
- Temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload . who have failed diuretic therapy, and
- Extended (longer than 8 hours) ultrafiltration treatment of patients with fluid . overload who have failed diuretic therapy and require hospitalization.
All treatments must be administered by a health care provider, under physician prescription, both of whom having received training in extracorporeal therapies.
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)
辅导服务员服务服务员员会长谢谢谢谢谢谢谢谢谢谢谢何将导师来来自己是非常用发展的家庭家庭和新闻发展的新闻发展的新闻网络新闻网站地址的新闻信息和新闻信息和信息信息和信息发展的意思的网络信息 Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | / |
|---|---|
| (Per 21 CFR 801.109) |
OR
| Over-The-Counter Use | __________ |
|---|---|
| ---------------------- | ------------ |
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
| 510(k) Number | K062922 |
|---|---|
| --------------- | --------- |
CHF Solutions, Inc. Aquadex FlexFlow Rev. K Software Update